NCT04009668 2024-10-30
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
University of Michigan
Phase 2 Completed
Clinical Trials
12 trialsNCT03180957 2024-06-28
RIDD
University of Oxford
Phase 2 Completed
NCT05073315 2024-02-09
A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis
Amgen
Phase 3 Completed
NCT00837434 2021-09-22
Anti-TNF Agents for the Treatment of Rheumatoid Arthritis
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 4 Completed
NCT02092467 2021-08-17
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Pfizer
Phase 4 Completed
NCT02163759 2021-07-23
HIBISCUS I
Hoffmann-La Roche
Phase 3 Completed
NCT00311246 2020-08-25
Trial of Adalimumab in Progressive Sarcoidosis
University of Chicago
Phase 2 Terminated
NCT02499783 2019-01-04
Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease
AbbVie
Phase 3 Completed
NCT02196701 2018-03-19
CLEAR
AbbVie
Phase 3 Completed
NCT02437253 2017-09-15
Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Phase 1/2 Completed
NCT00932113 2017-08-31
MOA
Tufts Medical Center
Phase 4 Completed
NCT01283971 2014-02-10
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor
Hoffmann-La Roche
Phase 4 Terminated